- Home
- BTAI vs GSIW Comparison
BTAI vs GSIW Comparison
Compare BTAI & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- GSIW
- Stock Information
- Founded
- BTAI 2017
- GSIW 2016
- Country
- BTAI United States
- GSIW Hong Kong
- Employees
- BTAI N/A
- GSIW N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- BTAI Health Care
- GSIW
- Exchange
- BTAI Nasdaq
- GSIW Nasdaq
- Market Cap
- BTAI 8.4M
- GSIW 8.3M
- IPO Year
- BTAI 2018
- GSIW 2023
- Fundamental
- Price
- BTAI $1.84
- GSIW $1.15
- Analyst Decision
- BTAI Buy
- GSIW
- Analyst Count
- BTAI 5
- GSIW 0
- Target Price
- BTAI $42.60
- GSIW N/A
- AVG Volume (30 Days)
- BTAI 436.1K
- GSIW 2.1M
- Earning Date
- BTAI 08-05-2025
- GSIW 12-31-2024
- Dividend Yield
- BTAI N/A
- GSIW N/A
- EPS Growth
- BTAI N/A
- GSIW N/A
- EPS
- BTAI N/A
- GSIW N/A
- Revenue
- BTAI $1,852,000.00
- GSIW $1,313,795.00
- Revenue This Year
- BTAI $5.03
- GSIW N/A
- Revenue Next Year
- BTAI $291.01
- GSIW N/A
- P/E Ratio
- BTAI N/A
- GSIW N/A
- Revenue Growth
- BTAI 5.47
- GSIW N/A
- 52 Week Low
- BTAI $1.17
- GSIW $0.35
- 52 Week High
- BTAI $25.92
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- BTAI 64.53
- GSIW 78.55
- Support Level
- BTAI $1.17
- GSIW $0.73
- Resistance Level
- BTAI $1.48
- GSIW $0.77
- Average True Range (ATR)
- BTAI 0.13
- GSIW 0.10
- MACD
- BTAI 0.06
- GSIW 0.03
- Stochastic Oscillator
- BTAI 100.00
- GSIW 86.84
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.